251 related articles for article (PubMed ID: 26222275)
1. Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer.
Ceresoli GL; De Vincenzo F; Sauta MG; Bonomi M; Zucali PA
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):374-80. PubMed ID: 26222275
[TBL] [Abstract][Full Text] [Related]
2. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
4. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
5. Should docetaxel be administered earlier in prostate cancer therapy?
Graff JN; Beer TM
Expert Rev Anticancer Ther; 2015; 15(9):977-9. PubMed ID: 26223224
[TBL] [Abstract][Full Text] [Related]
6. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
Fizazi K; Jenkins C; Tannock IF
Ann Oncol; 2015 Aug; 26(8):1660-7. PubMed ID: 26002607
[TBL] [Abstract][Full Text] [Related]
7. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
García de Paredes Esteban JC; Alegre Del Rey EJ; Asensi Díez R
Farm Hosp; 2017 Jul; 41(4):550-558. PubMed ID: 28683707
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
10. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
van Soest RJ; de Wit R
BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
12. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
13. Upfront Chemotherapy for Metastatic Prostate Cancer.
Lam ET; Flaig TW
Oncology (Williston Park); 2015 Dec; 29(12):956-62. PubMed ID: 26676900
[TBL] [Abstract][Full Text] [Related]
14. [Docetaxel for metastatic prostate cancer: early is better].
Gietema JA; Oosting SF
Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for metastatic castrate-sensitive prostate cancer.
Miller RE; Sweeney CJ
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365
[TBL] [Abstract][Full Text] [Related]
16. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
Marino P; Sfumato P; Joly F; Fizazi K; Oudard S; Culine S; Habibian M; Boher JM; Gravis G
Eur J Cancer; 2017 Oct; 84():27-33. PubMed ID: 28780479
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
[TBL] [Abstract][Full Text] [Related]
18. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Xu L; Pachynski RK
Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
Gravis G; Audenet F; Irani J; Timsit MO; Barthelemy P; Beuzeboc P; Fléchon A; Linassier C; Oudard S; Rebillard X; Richaud P; Rouprêt M; Thiery Vuillemin A; Vincendeau S; Albiges L; Rozet F
Cancer Treat Rev; 2017 Apr; 55():211-217. PubMed ID: 27665366
[TBL] [Abstract][Full Text] [Related]
20. Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy.
Lee JL; Eun Kim J; Ahn JH; Lee DH; Lee J; Kim CS; Hyuk Hong J; Hong B; Song C; Ahn H
Am J Clin Oncol; 2011 Apr; 34(2):140-4. PubMed ID: 20686407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]